



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## Regd. Office & Factory

Plot No. A2/3445, GIDC,  
Phase 4, Ankleshwar – 393 002,  
Gujarat, India  
Tel : +91-7045456789 / 7046456789  
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

## Corporate Office

701/702, Business Square,  
M. A. Road, Andheri (West),  
Mumbai – 400 058, India  
Tel : (91-22) 26701050 / 1 / 2 / 3  
Email: contact@samratpharmachem.in

**November 13, 2021**

To,  
**Department of Corporate Services,  
BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.

**Scrip Code: 530125**

Dear Sir,

**Sub: Approval of Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2021**

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Saturday, November 13, 2021, the Board has considered and took on record the Un-Audited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2021, which is enclosed herewith along with the Statement of Asset & Liabilities, Cash Flow Statement and the Limited Review Report of the Statutory Auditor of the Company.

The meeting of the Board of Directors of the Company commenced at 13:00 hrs and concluded at 14:00 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,  
**For Samrat Pharmachem Limited**

**Nishant Kankaria**  
**Company Secretary & Compliance Officer**



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Statement of Standalone Unaudited Results for the Quarter Ended 30 September, 2021

(Rupees in Lakhs)

Particulars	Quarter Ended 30-Sep-21 (Unaudited)	Quarter Ended 30-Jun-21 (Unaudited)	Quarter Ended 30-Sep-20 (Unaudited)	Year to date ended 30-Sep-21 (Unaudited)	Year to date ended 30-Sep-20 (Unaudited)	Year Ended 31-Mar-21 (Audited)
1 (a) Revenue from Operations	5,907.62	4,723.86	4,149.73	10,631.49	7,676.40	17,901.78
(b) Other Income	7.25	15.31	2.28	22.56	4.19	46.28
Total Revenue	5,914.87	4,739.17	4,152.01	10,654.05	7,680.59	17,948.06
2. Expenditure						
a) Cost of materials consumed	5,213.81	4,495.81	3,974.10	9,709.62	6,672.46	16,201.76
b) Purchase of Traded Goods	0.00	0.00	0.00	0.00	0.00	0.00
c) Change in Inventories of Finished Goods and Work-in-Progress	116.79	-65.16	-243.35	51.62	331.35	222.75
d) Employee Costs	39.84	38.02	30.19	77.86	57.83	149.80
e) Interest	20.66	17.43	28.09	38.09	73.98	127.67
f) Depreciation & Amortisation expense	14.76	14.49	11.89	29.25	23.10	49.29
g) Other Expenses	121.89	112.81	122.70	234.68	186.95	460.64
(i) Manufacturing Expenses	76.48	89.44	78.49	165.92	128.58	286.50
(ii) Administration Expenses	18.55	13.91	21.14	32.45	29.90	72.44
(iii) Selling & Distribution Expenses	26.86	9.46	23.07	36.31	28.47	101.70
Total	5,527.75	4,613.40	3,923.62	10,141.12	7,345.67	17,211.91
3. Profit before exceptional & extraordinary items & tax	387.12	125.77	228.39	512.93	334.92	736.15
4. Exceptional Items	0.00	0.00	0.00	0.00	0.00	-1.77
5. Profit before extraordinary items & tax	387.12	125.77	228.39	512.93	334.92	734.38
6. Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
7. Profit before tax	387.12	125.77	228.39	512.93	334.92	734.38
8. Tax expense						
a) Current Tax	-94.42	-29.83	-70.91	-124.25	-81.56	-172.29
b) Deferred Tax	-13.75	-0.60	-13.53	-14.35	-29.61	-28.78
Total Tax Expense	-108.17	-30.43	-84.44	-138.60	-111.17	-201.07
9. Profit (Loss) for the period after tax	278.95	95.34	143.95	374.33	223.75	533.31
10. Other Comprehensive Income (OCI)						
a(i) Items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
b(i) Items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be re-classified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
Total Other comprehensive income, net of income tax	0.00	0.00	0.00	0.00	0.00	0.00
11. Total Comprehensive Income for the period	278.95	95.34	143.95	374.33	223.75	533.31
12. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97	308.97
13. Earnings per equity share						
a) Basic	9.03	3.09	4.66	12.12	7.24	17.26
b) Diluted	9.03	3.09	4.66	12.12	7.24	17.26



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

**Notes:**

1. The above results were reviewed by the Audit Committee of the Board of Directors.
2. The Statutory Auditors have carried out a limited review of the results for the quarter ended 30 September, 2021.
3. The above unaudited results have been taken on record by the Board of Directors at its Meeting held on Saturday, 13 November 2021 at the Corporate Office of the Company.
4. The Company has adopted Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from 01 April 2017 (with a transition date of 01 April 2016). Accordingly the financial results for the quarter ended 30 September 2021 have been prepared in accordance with Companies (Indian Accounting Standard) Rules, 2015 as prescribed under section 133 of the Companies Act, 2013.
5. The Company manufactures pharmaceutical chemicals, which is a single business segment.
6. Figures for the previous period have been regrouped / reclassified, wherever necessary.

**By order of the Board of Directors  
For Samrat Pharmachem Limited**

**Rajesh Mehta  
Executive Director  
DIN: 00216731**

**Place : Mumbai  
Date : 13 November 2021**



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## Statement of Assets & Liabilities

(Rs. in lakhs) (Rs. in lakhs)

PARTICULARS	Standalone	Standalone
	AS ON 30-Sep-21 Un-Audited	AS ON 31-Mar-21 Audited
<b>ASSETS</b>		
<b>Non Current Assets</b>		
Property, Plant and Equipment	945.14	939.39
Capital Work-in-progress	-	0
Intangible Assets	0.89	0.94
Intangible Assets under development	-	0
Financial Assets		
Investments	-	-
Loans	21.42	20.47
Deferred Tax Assets (Net)	-	-
Other Non-Current Assets	53.67	46.46
<b>Total Non Current Assets</b>	<b>1,021.12</b>	<b>1,007.26</b>
<b>CURRENT ASSETS</b>		
Inventories	1,167.90	1,139.99
Financial Assets		
Investments	0.10	0.10
Trade Receivables	4,516.44	3,300.54
Cash And Cash Equivalents	657.41	254.26
Loans	-	1.80
Other Financial Assets	-	-
Other Current Assets	101.25	35.70
<b>Total Current Assets</b>	<b>6,443.10</b>	<b>4,732.39</b>
<b>Total- Assets</b>	<b>7,464.22</b>	<b>5,739.65</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share Capital	308.97	308.97
Other Equity	3,029.04	2,654.72
<b>Total Equity</b>	<b>3,338.01</b>	<b>2,963.69</b>
<b>Non-Current Liabilities</b>		
Financial Liabilities		
Borrowings	-	-
Provisions	-	-
Deferred Tax Liabilities (Net)	57.60	43.26
Other Long Current Liabilities	-	-
<b>Total Non-Current Liabilities</b>	<b>57.60</b>	<b>43.26</b>
<b>Current Liabilities</b>		
Financial Liabilities		
Borrowings	977.19	879.37
Trade Payables	2,937.62	1,766.01
Other Financial Liabilities	-	-
Other Current Liabilities	61.76	17.09
Provisions	92.04	70.23
<b>Total Current Liabilities</b>	<b>4,068.61</b>	<b>2,732.70</b>
<b>Total Liabilities</b>	<b>7,464.22</b>	<b>5,739.65</b>



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

## CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30 SEPTEMBER, 2021

(Rupees in Lakhs)

Particulars	Half year ended 30-Sep-2021 (Unaudited)	Half year ended 30-Sep-2020 (Unaudited)
<b>A. CASH FLOW FROM OPERATING ACTIVITIES</b>		
Profit / (Loss) before tax	512.92	334.93
Adjustments For :		
Depreciation and amortization expense	29.25	23.10
(Gain) / Loss on Sale/write off of property, plant and equipment and intangible assets, net	-0.37	0.88
Finance Cost	38.09	73.98
Interest Income	-3.45	-1.58
Dividend Income on investments	-0.17	0.00
Net loss arising on financial assets measured at fair value through profit or loss	0.00	0.00
Net gain on sale of arising on financial assets measured at fair value through profit or loss	0.00	0.00
Net (gain)/ loss on sale of financial assets measured at fair value through other comprehensive income	0.00	0.00
Gain On Sale of Investment in subsidiary	0.00	0.00
Provision/write off/ (reversal) for doubtful trade receivables / advances	0.00	0.00
Sundry balances written back, net	0.00	0.00
Provision in respect of losses of a subsidiary	0.00	0.00
Effect of exchange rate changes	0.00	0.00
	63.35	96.38
<b>Operating Profit Before Working Capital Changes</b>	576.27	431.31
<b>Movements in working capital:</b>		
(Increase) / decrease in inventories	-27.92	356.90
(Increase) / decrease in trade receivables	-1,215.90	-185.01
(Increase) / decrease in other assets	-71.91	153.92
Increase / (decrease) in trade payables	1,171.59	6.55
Increase / (decrease) in other liabilities	44.67	40.84
Increase / (decrease) in provisions	0.15	0.00
	-99.32	373.20
<b>Cash Generated From Operations</b>	476.95	804.51
Income Tax Paid (net of refund)	-102.59	-123.11
<b>Net cash generated from operating activities (A)</b>	374.36	681.40
<b>B. CASH FLOW FROM INVESTING ACTIVITIES</b>		
Payments for purchase of property, plant and equipment (including capital work-in-progress, intangible assets and intangible assets under development)	-34.58	-35.06
Proceeds from disposal of property, plant and equipment and intangible assets	0.00	0.00
Loans / Inter corporate deposits given / placed	0.00	0.00
Loans / Inter corporate deposits received back / matured	0.00	0.00
Purchase of investments	0.00	0.00
Proceeds from sale / redemption of investments	0.00	0.00
Bank balances not considered as cash and cash equivalents		
Fixed deposits / margin money placed	-80.00	-174.00
Fixed deposits / margin money matured	0.00	0.00
Interest received	3.45	1.58
Dividend received	0.17	0.00
<b>Net cash from investing activities (B)</b>	-110.96	-207.48
	Continued ...	



# Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Particulars	30-09-2021 Rs.	30-09-2020 Rs.
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds From Issue of equity shares on exercise of stock options / share application money received	0.00	0.00
Proceeds from borrowings	185.08	-78.14
Repayment of borrowings	-87.25	-31.21
Finance costs	-38.09	-73.98
Dividend paid	0.00	0.00
Dividend distribution tax	0.00	0.00
<b>Net Cash from / (Used) In Financing Activities (C)</b>	<b>59.74</b>	<b>-183.33</b>
<b>NET INCREASE/ (DECREASE) IN CASH AND CASH EQUIVALENTS (A+B+C)</b>	<b>323.15</b>	<b>290.59</b>
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD (Opening Balance)	27.86	25.74
EFFECT OF EXCHANGE DIFFERENCES ON RESTATEMENT OF FOREIGN CURRENCY CASH AND CASH EQUIVALENTS	0.00	0.00
<b>CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD (Closing Balance)</b>	<b>351.01</b>	<b>316.33</b>

By order of the Board of Directors  
For Samrat Pharmachem Limited

Rajesh Mehta  
Executive Director  
DIN: 00216731

Place : Mumbai  
Date : 13 November 2021



# Shah & Savla LLP

Chartered Accountants

CA Mulesh Savla  
Advisory & Regulatory

CA Nilesh Dedhia  
Direct Tax & Litigation

CA Miral Nagda  
Audit & Assurance


CA Nihar Dharod  
Indirect Tax & Litigation

Independent Auditor's Review Report on Quarterly and Year-to-date Unaudited Financial Results of the Company pursuant to the regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015, as amended

To the Board of Directors of Samrat Pharmachem Limited

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 30<sup>th</sup> September, 2021 and year to date results for the period from 01 April 2021 to 30 September 2021 (the "statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors / Committee of Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shah & Savla LLP  
Chartered Accountants  
Firm Reg: No.:109364W/W100143

  
CA. Mulesh M. Savla  
(Partner)  
Membership No. 038404



UDIN : 21038404AAAA8G8883  
Place: Mumbai  
Date: 13<sup>th</sup> November, 2021